Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines

References

• Hossain MJ, Rahman SMA. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Expert Rev Anti Infect Ther. 2021;19(8):1009–5. doi:10.1080/14787210.2021.1864327.
   PubMed Web of Science ®Google Scholar
• Konings F, Perkins MD, Kuhn JH, Pallen MJ, Alm EJ, Archer BN, Barakat A, Bedford T, Bhiman JN, Caly L, et al. SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse. Nat Microbiol. 2021;6(7):821–23. doi:10.1038/s41564-021-00932-w.
   PubMed Web of Science ®Google Scholar
• Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Mutair A. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother. 2021 Oct 3;17(10):3491–94. doi:10.1080/21645515.2021.1923350.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA. 2021;325(13):1261–62. doi:10.1001/jama.2021.2088.
   PubMed Web of Science ®Google Scholar
• Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Immunol. 2021;21(6):340–41. doi:10.1038/s41577-021-00556-5.
   PubMed Web of Science ®Google Scholar
• Farinholt T, Doddapaneni H, Qin X, Menon V, Meng Q, Metcalf G, Chao H, Gingras MC, Avadhanula V, Farinholt P, et al. Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. BMC Med. 2021;19(1):255. doi:10.1186/s12916-021-02103-4.
   PubMed Web of Science ®Google Scholar
• Hossain MJ, Soma MA, Islam MR, Emran TB. Urgent call for actionable measures to fight the current co-epidemic of dengue burden during the SARS-CoV-2 delta variant era in South-Asia. Ethics Med Public Health. 2021;19:100726. doi:10.1016/j.jemep.2021.100726.
   PubMedGoogle Scholar
• Wang R, Chen J, Hozumi Y, Yin C, Wei GW. Emerging vaccine-breakthrough SARS-CoV-2 variants. ArXiv [Preprint]. 2021;2109.04509v1.
   Google Scholar
• CDC. SARS-CoV-2 variant classifications and definitions. [accessed 2021 Oct 23]. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html .
   Google Scholar
• WHO. Tracking SARS-CoV-2 variants. [accessed 2021 Oct 23]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ .
   Google Scholar
• Chen J, Wang R, Wei GW. Review of the mechanisms of SARS-CoV-2 evolution and transmission. ArXiv [Preprint]. 2021 Sep;15:2109.08148v1.
   Google Scholar
• Rophina M, Pandhare K, Shamnath A, Imran M, Jolly B, Scaria V. ESC: a comprehensive resource for SARS-CoV-2 immune escape variants. Nucleic Acids Res. 2021:gkab895. doi:10.1093/nar/gkab895.
   Web of Science ®Google Scholar
• Thye AY, Law JW, Pusparajah P, Letchumanan V, Chan KG, Lee LH. Emerging SARS-CoV-2 Variants of Concern (VOCs): an impending global crisis. Biomedicines. 2021 Sep 23;9(10):1303. doi:10.3390/biomedicines9101303.
   PubMed Web of Science ®Google Scholar
• Tian D, Sun Y, Zhou J, Ye Q. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. J Med Virol. 2021 Oct 5. doi:10.1002/jmv.27376.
   Web of Science ®Google Scholar
• Torbati E, Krause KL, Ussher JE. The immune response to SARS-CoV-2 and variants of concern. Viruses. 2021;13(10):1911. doi:10.3390/v13101911.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Huang J, Zhang L, Chen S, Gao J, Jiao H. The global transmission of new coronavirus variants. Environ Res. 2021:112240. doi:10.1016/j.envres.2021.112240.
   PubMed Web of Science ®Google Scholar
• News 18. As scientists monitor growth rate of AY 4.2, the covid subvariant is taking hold of UK, spreading in Russia. [accessed 2021 Nov 4]. https://www.news18.com/news/world/as-scientists-monitor-the-growth-rate-of-delta-plus-the-subvariant-is-taking-hold-of-uk-spreading-in-russia-4354619.html .
   Google Scholar
• WION. New virus variant in Russia may be more contagious: report. [accessed 2021 Nov 4]. https://www.wionews.com/world/new-virus-variant-in-russia-may-be-more-contagious-report-422780 .
   Google Scholar
• Reuters. Russia reports cases of more contagious COVID-19 delta subvariant. [accessed 2021 Nov 4]. https://www.reuters.com/world/europe/russia-reports-cases-more-contagious-covid-19-variant-reports-2021-10-21/ .
   Google Scholar
• WHO. Weekly epidemiological update on COVID-19. 2021 Aug 31 [accessed 2021 Nov 4]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—31-august-2021 .
   Google Scholar
• Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Prada DA, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021;95:105038. doi:10.1016/j.meegid.2021.105038.
   PubMed Web of Science ®Google Scholar
• UN. COVID-19: new Mu variant could be more vaccine-resistant. [accessed 2021 Oct 23]. https://news.un.org/en/story/2021/09/1098942 .
   Google Scholar
• Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-A, Kaneda A, Nakagawa S, Sato K. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. N Engl J Med. 2021;385(25):2397–99. doi:10.1056/NEJMc2114706.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–35. doi:10.1038/s41586-021-03398-2.
   PubMed Web of Science ®Google Scholar
• Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T, Kaneda A, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Nakagawa, S, Sato, K, Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. bioRxiv. 2021 September 06:459005. doi:10.1101/2021.09.06.459005.
   Google Scholar
• Messali S, Bertelli A, Campisi G, Zani A, Ciccozzi M, Caruso A, Caccuri F. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine. J Med Virol. 2021;93(12):6468–70. doi:10.1002/jmv.27247.
   PubMed Web of Science ®Google Scholar
• Xie X, Han JB, Ma G, Feng XL, Li X, Zou QC, Deng ZH, Zeng J. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res. 2021;42(6):789–91. doi:10.24272/j.2095-8137.2021.343.
   PubMed Web of Science ®Google Scholar
• Bari MS, Hossain MJ, Akhter S, Emran TB. Delta variant and black fungal invasion: a bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Ethics Med Public Health. 2021;19:100722. doi:10.1016/j.jemep.2021.100722.
   PubMedGoogle Scholar
• Hossain MJ, Rahman SMA, Emran TB, Mitra S, Islam MR, Dhama K. Recommendation and roadmap of mass vaccination against COVID-19 pandemic in Bangladesh as a Lower-Middle-Income Country (LMIC). Arch Razi Inst. 2021. doi:10.22092/ari.2021.356357.1824.
   PubMedGoogle Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2021;26:S1198-743X(21)00604–2. doi:10.1016/j.cmi.2021.10.005.
   Google Scholar
• Khan A, Khan T, Ali S, Aftab S, Wang Y, Qiankun W, Khan M, Suleman M, Ali S, Heng W, et al. SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 2021;143:112176. doi:10.1016/j.biopha.2021.112176.
   PubMed Web of Science ®Google Scholar
• Burki T. Understanding variants of SARS-CoV-2. Lancet. 2021 Feb 6;397(10273):462. doi:10.1016/S0140-6736(21)00298-1.
   PubMed Web of Science ®Google Scholar
• Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, Hill SC, Sabino EC, Pybus OG, Dye C, et al. Global disparities in SARS-CoV-2 genomic surveillance. medRxiv. 2021. doi:10.1101/2021.08.21.21262393.
   Google Scholar
• Tareq AM, Emran TB, Dhama K, Dhawan M, Tallei TE. Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Hum Vaccin Immunother. 2021:1–2. doi:10.1080/21645515.2021.1963601.
   Web of Science ®Google Scholar
• Sharun K, Dhama K. COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Arch Med Res. 2021:S0188-4409(21)00112–0. doi:10.1016/j.arcmed.2021.04.006.
   PubMed Web of Science ®Google Scholar
• Obinna DN. Solidarity across borders: a pragmatic need for global COVID-19 vaccine equity. Int J Health Plann Manage. 2021. doi:10.1002/hpm.3341.
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang W. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal Transduct Target Ther. 2021;6(1):226. doi:10.1038/s41392-021-00644-x.
   PubMed Web of Science ®Google Scholar
• Varshney SK, Prasanna NK. Vaccine diplomacy: exploring the benefits of international collaboration. Trends Biotechnol. 2021;15:110–14. doi:10.5530/ctbp.2021.1.12.
   Google Scholar
• Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–86. doi:10.1056/NEJMsr2105280.
   PubMed Web of Science ®Google Scholar
• CBS NWES. Pfizer says its booster shot restores full COVID-19 protection. [accessed 2021 Oct 23]. https://www.msn.com/en-us/health/medical/pfizer-says-its-booster-shot-restores-full-covid-19-protection/ar-AAPN15n?ocid=BingNewsSearch .
   Google Scholar
• Müller O, Razum O, Jahn A. Effects of non-pharmaceutical interventions against COVID-19 on the incidence of other diseases. Lancet Reg Health Eur. 2021 Jul;6:100139. Epub 2021 Jun 27. PMID: 34223441; PMCID: PMC8236073. doi:10.1016/j.lanepe.2021.100139.
   PubMedGoogle Scholar
• Rahimi F, Talebi Bezmin Abadi A. Criticality of physical/social distancing, handwashing, respiratory hygiene and face-masking during the COVID-19 pandemic and beyond. Int J Clin Pract. 2020;74(11):e13656. doi:10.1111/ijcp.13656.
   PubMed Web of Science ®Google Scholar
• Su Z, Wen J, McDonnell D, Goh E, Li X, Šegalo S, Ahmad J, Cheshmehzangi A, Xiang YT. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. doi:10.1016/j.bbih.2021.100204.
   PubMedGoogle Scholar
• Choudhary OP, Priyanka, Singh I. Vaccine certificate during domestic traveling: a potential initiative to prevent COVID-19 waves in India. Hum Vaccin Immunother. 2021;17(10):3487–88. doi:10.1080/21645515.2021.1936862.
   PubMed Web of Science ®Google Scholar
• Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, Amati F. SARS-CoV-2 vaccines: a critical perspective through efficacy data and barriers to herd immunity. Respir Med. 2021;180:106355. doi:10.1016/j.rmed.2021.106355.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy-reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021:1–5. doi:10.1080/21645515.2021.1926183.
   Web of Science ®Google Scholar
• Farooqi T, Malik JA, Mulla AH, Al Hagbani T, Almansour K, Ubaid MA, Alghamdi S, Anwar S. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):SS1876–X. doi:10.1016/j.jiph.2021.08.014.
   Web of Science ®Google Scholar
• Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013–25. doi:10.1080/14760584.2021.1949293.
   PubMed Web of Science ®Google Scholar
• Raman R, Patel KJ, Ranjan K. COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules. 2021;11(7):993. doi:10.3390/biom11070993.
   PubMed Web of Science ®Google Scholar
• Redwan EM. COVID-19 pandemic and vaccination build herd immunity. Eur Rev Med Pharmacol Sci. 2021;25(2):577–79. doi:10.26355/eurrev_202101_24613.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023–34. doi:10.1016/S0140-6736(21)00306-8.
   PubMed Web of Science ®Google Scholar
• Yan ZP, Yang M, Lai CL. COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals. 2021;14(5):406. doi:10.3390/ph14050406.
   Web of Science ®Google Scholar
• Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Geneva centre for emerging viral diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021 Aug;27(8):1109–17. doi:10.1016/j.cmi.2021.05.022.
   PubMed Web of Science ®Google Scholar
• Caldwell JM, Le X, McIntosh L, Meehan MT, Ogunlade S, Ragonnet R, O’Neill GK, Trauer JM, McBryde ES. Vaccines and variants: modelling insights into emerging issues in COVID-19 epidemiology. Paediatr Respir Rev. 2021;39:32–39. doi:10.1016/j.prrv.2021.07.002.
   PubMed Web of Science ®Google Scholar
• Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell. 2021 Sep 30;184(20):5077–81. doi:10.1016/j.cell.2021.09.010.
   PubMed Web of Science ®Google Scholar
• Günl F, Mecate-Zambrano A, Rehländer S, Hinse S, Ludwig S, Brunotte L. Shooting at a moving target-effectiveness and emerging challenges for SARS-CoV-2 Vaccine Development. Vaccines. 2021;9(10):1052. doi:10.3390/vaccines9101052.
   Web of Science ®Google Scholar
• Khan WH, Hashmi Z, Goel A, Ahmad R, Gupta K, Khan N, Alam I, Ahmed F, Ansari MA. COVID-19 pandemic and vaccines update on challenges and resolutions. Front Cell Infect Microbiol. 2021;11:690621. doi:10.3389/fcimb.2021.690621.
   PubMed Web of Science ®Google Scholar
• Salimi-Jeda A, Abbassi S, Mousavizadeh A, Esghaie M, Bokharaei-Salim F, Jeddi F, Shafaati M, Abdoli A. SARS-CoV-2: current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. Int Immunopharmacol. 2021;101(Pt A):108232. doi:10.1016/j.intimp.2021.108232.
   PubMed Web of Science ®Google Scholar